Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies. We and others have previously established bortezomib, a selective proteasome inhibitor, as an important potential treatme...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Octavian Bucur, Andreea Lucia Stancu, Ioana Goganau, Stefana Maria Petrescu, Bodvael Pennarun, Thierry Bertomeu, Rajan Dewar, Roya Khosravi-Far
Materialtyp: Artikel
Språk:English
Publicerad: Public Library of Science (PLoS) 2013-01-01
Serie:PLoS ONE
Länkar:http://europepmc.org/articles/PMC3796452?pdf=render

Internet

http://europepmc.org/articles/PMC3796452?pdf=render

Liknande verk